Retatrutide Dosage: Clinical Trial Protocols and Escalation Schedule

Key takeaways

• Clinical trials used a 2 mg → 4 mg → 8 mg → 12 mg escalation, increasing every 4 weeks
• Starting at 2 mg (rather than 4 mg) reduced gastrointestinal side effects during titration
• The 12 mg dose produced the highest weight loss (24.2% at 48 weeks in phase 2)
• All doses are administered once weekly by subcutaneous injection
• No official prescribing information exists since retatrutide is not FDA-approved

Since retatrutide is still in clinical trials and has no FDA approval, there is no official prescribing information. Everything below comes from published clinical trial protocols. This is not medical advice or a dosing recommendation.

The phase 2 trial by Jastreboff et al. (2023) tested multiple dose levels and starting-dose strategies, giving us a clear picture of how the drug was administered and what each dose level achieved [1].

The standard escalation protocol

The dosing schedule that produced the best balance of efficacy and tolerability in the phase 2 trial:

Weeks	Weekly dose	Purpose
1-4	2 mg	Initial dose, GI acclimation
5-8	4 mg	First escalation
9-12	8 mg	Second escalation
13+	12 mg	Maintenance dose

Each step doubles (or nearly doubles) the dose. The 4-week intervals give the body time to adjust to each level before moving up. This is the same general approach used with semaglutide and tirzepatide, though the specific doses and timelines differ [1].

Why dose escalation matters

The phase 2 trial tested two different starting doses for the 4 mg and 8 mg groups: some participants began at 2 mg and escalated, while others started directly at the target dose (4 mg) [1].

The results were clear. Participants who started at 2 mg and escalated had fewer gastrointestinal side effects during the first weeks of treatment. Nausea, vomiting, and diarrhea were all less frequent with the slower start [1].

This isn’t unique to retatrutide. GLP-1 receptor agonists slow gastric emptying, and starting at a full dose overwhelms the GI tract before it can adapt. The gradual approach is standard practice across this drug class. What the retatrutide data confirms is that the principle applies just as strongly (maybe more so) when three receptors are being activated instead of one or two.

Dose-response: what each level achieves

The phase 2 trial tested doses from 1 mg to 12 mg. Here’s how weight loss scaled with dose at 48 weeks [1]:

Dose	Weight loss at 48 weeks	≥5% loss	≥10% loss	≥15% loss
1 mg	-8.7%	Not reported	Not reported	Not reported
4 mg	-17.1%	92%	75%	60%
8 mg	-22.8%	100%	91%	75%
12 mg	-24.2%	100%	93%	83%
Placebo	-2.1%	27%	9%	2%

The difference between 8 mg and 12 mg (22.8% vs. 24.2%) is smaller than the jump from 4 mg to 8 mg (17.1% vs. 22.8%). This suggests diminishing returns at the highest dose, which matters when weighing efficacy against side effect burden [1].

In the phase 3 TRIUMPH-4 trial, which ran for 68 weeks (20 weeks longer than phase 2), the 12 mg dose produced 28.7% body weight loss. The weight loss curve still appeared to be trending downward at the end of the trial [2].

Phase 3 dosing (TRIUMPH program)

The TRIUMPH phase 3 trials tested 9 mg and 12 mg doses. The decision to drop the lower doses from phase 3 reflects the clear dose-response relationship from phase 2: the 8 mg and 12 mg groups had substantially better outcomes than the 1 mg and 4 mg groups [2].

The escalation protocol in phase 3 followed the same principle of gradual titration, though the specific steps for reaching 9 mg vs. 12 mg maintenance doses haven’t been detailed in the public topline results.

How to administer retatrutide injections

Retatrutide is administered as a once-weekly subcutaneous injection. Based on the clinical trial protocol [1]:

Injection sites: Abdomen (at least 2 inches from the navel), front of the thigh, or back of the upper arm. Rotate between sites to prevent injection site reactions.

Timing: Same day each week. In the trial, no specific time of day was mandated. Patients typically choose a consistent day and time that works for their schedule.

Storage: Clinical trial supply was stored refrigerated (2-8°C / 36-46°F). Specific storage requirements for any future commercial product will be in the prescribing information.

If you’re unfamiliar with subcutaneous injection technique, see our guides on how to inject peptides and peptide injection sites.

What happens if you miss a dose

The phase 2 trial protocol treated retatrutide as a once-weekly medication. While the published study doesn’t detail the specific missed-dose protocol, the general approach for weekly GLP-1 agonists is [3]:

• If you remember within a few days of the missed dose, take it as soon as possible
• If it’s close to your next scheduled dose, skip the missed one and resume your regular schedule
• Don’t double up doses to make up for a missed injection
• If multiple doses are missed, consult your provider about whether to resume at the current dose or step back down

The long half-life of retatrutide (enabled by its C20 fatty diacid moiety) means one missed dose shouldn’t dramatically alter drug levels, but extended gaps could reduce efficacy and potentially re-trigger GI side effects when restarting [1].

Dosing considerations

Starting dose

The phase 2 data makes a strong case for starting at 2 mg regardless of target maintenance dose. The groups that started at higher doses had more GI side effects without meaningfully better long-term outcomes [1].

Maintenance dose

The trial data suggests 8 mg and 12 mg produce the most weight loss. The choice between them involves a trade-off: 12 mg produces about 1.4 percentage points more weight loss at 48 weeks but comes with higher rates of nausea and the dysesthesia signal seen in phase 3 [1, 2].

Ultimately, the right dose will be determined by a healthcare provider based on individual response, tolerability, and treatment goals. Some patients may achieve sufficient results at 8 mg without needing to escalate further.

Extended escalation

For patients who struggle with GI side effects at each escalation, holding at a given dose for 6-8 weeks (instead of the standard 4 weeks) before increasing may improve tolerability. This approach trades a slower path to full efficacy for fewer side effects along the way [1].

Retatrutide dosing vs. other GLP-1 medications

Feature	Retatrutide	Tirzepatide (Mounjaro)	Semaglutide (Wegovy)
Starting dose	2 mg	2.5 mg	0.25 mg
Maintenance dose	8-12 mg	5-15 mg	2.4 mg
Escalation interval	Every 4 weeks	Every 4 weeks	Every 4 weeks
Frequency	Once weekly	Once weekly	Once weekly
Route	Subcutaneous	Subcutaneous	Subcutaneous
Time to full dose	~12 weeks	~16-20 weeks	~16-20 weeks

Retatrutide reaches its maintenance dose faster than tirzepatide or semaglutide, though this partly reflects different dose ranges rather than a fundamentally different escalation philosophy.

For a full comparison of these medications, see our weight loss peptides guide.

Frequently asked questions

What is the best retatrutide dose for weight loss?▼

In clinical trials, the 12 mg dose produced the most weight loss: 24.2% at 48 weeks (phase 2) and 28.7% at 68 weeks (phase 3). The 8 mg dose produced 22.8% at 48 weeks. The difference is modest, and some patients may prefer 8 mg to reduce side effect risk [1, 2].

How long does it take for retatrutide to start working?▼

Weight loss typically begins within the first 4 weeks of treatment, even at the starting dose of 2 mg. In the phase 2 trial, the 12 mg group had already lost 17.5% of body weight by week 24. Appetite reduction usually appears within the first week or two of treatment [1].

Can I start at a higher dose to lose weight faster?▼

This is not recommended based on the clinical data. Starting at higher doses increased GI side effects without improving long-term weight loss outcomes. The 2 mg starting dose is specifically designed to let your body adjust before escalating [1].

How long do you take retatrutide?▼

The phase 2 trial ran for 48 weeks and the phase 3 trial for 68 weeks. Like other GLP-1 medications, retatrutide is intended for ongoing use. Stopping treatment is associated with weight regain based on data from similar drugs. The optimal treatment duration hasn’t been established yet [1, 2].

Is retatrutide injected or taken orally?▼

Retatrutide is administered by subcutaneous injection once weekly. There is currently no oral formulation. The injection is self-administered using a small needle, similar to other peptide injections. For injection technique guidance, see our guide on how to inject peptides.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Eli Lilly. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Press release. December 11, 2025.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.